Brief: InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum
06/11/2023 14:09
Nov 6 (Reuters) - InflaRx NV IF0G.F :
* INFLARX ANNOUNCES FIRST PATIENT DOSED IN PHASE III TRIAL
WITH
VILOBELIMAB IN PYODERMA GANGRENOSUM
* INFLARX NV: PRIMARY ENDPOINT OF STUDY IS COMPLETE CLOSURE
OF
TARGET ULCER AT ANY TIME UP TO 26 WEEKS AFTER INITIATION OF
TREATMENT
Source text for Eikon: ID:nGNX9R2mqs
Further company coverage: IF0G.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inflarx NV
See all newsBrief: Inflarx NV Files For Offerng Of Ordinary Shares, Size Not Disclosed - SEC Filing
Brief: InflaRx Reports Full Year 2025 Results And Highlights Key Achievements And Expected Milestones
Brief: Inflarx Announces Late-Breaker Oral Presentation On Vilobelimab Phase 3 Results In Pyoderma Gangrenosum At 2026 American Academy Of Dermatology Annual Meeting
Brief: Inflarx NV Executing 30% Workforce Reduction
Brief: Inflarx Provides Update On Phase 3 Data Analyses For Vilobelimab In Pyoderma Gangrenosum